Haldol

(Haloperidol Decanoate)

ApprovedSmall molecule

WWim Janssens

Haldol is one of 162 small molecule programs targeting Tic Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

161

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Tic DisorderActive, not recruiting

Schizoaffective DisorderActive, not recruiting

DeliriumActive, not recruiting

SchizophreniaActive, not recruiting

Tic DisorderPhase 3

Active, not recruiting

Schizoaffective DisorderPreclinical

Active, not recruiting

DeliriumApproved

Active, not recruiting

SchizophreniaApproved

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Haldol

WWim Janssens

Approved

2 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Zocor

OOrganon and Co

Preclinical

6 5

Ibrance

Pfizer

Preclinical

—6

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 7

Rapamune

PPrism Pharmaceuticals

Preclinical

1 8

Permax

VValeant Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Compazine

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Delirium

NCT01949662

Clinical

Trials by Indication[1]

Schizophrenia2 trials

Lamictal TM, Haloperidol Decanoate in Schizophrenia

Terminated·CCentral Mental Clinic for Outpatients of Baku City·Phase 4·NCT00947375·335 enrolled

A Comparison of Long-acting Injectable Medications for Schizophrenia

Completed·NNew York State Psychiatric Institute·Phase 4·NCT01136772·311 enrolled

Delirium2 trials

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01949662·93 enrolled

Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol

Completed·—·Phase 4·NCT01174290·68 enrolled

Tic Disorder1 trial

Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

Completed·—·Phase 3·NCT04327843·22 enrolled

TIPS1 trial

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

Completed·UUniversity Hospitals Cleveland Medical Center·N/A·NCT01152697·30 enrolled

Schizoaffective Disorder1 trial

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

Completed·UUS Department of Veterans Affairs·N/A·NCT00018642

Regulatory

FDA Approval Timeline[4]

Jan 14, 1986

HALDOL

NDA NDA018701

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Haloperidol Decanoate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Haloperidol Decanoate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Haloperidol Decanoate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018701). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wim Janssens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWim Janssens

Haldol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Schizophrenia2 trials

Delirium2 trials

Tic Disorder1 trial

TIPS1 trial

Schizoaffective Disorder1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News